| Business Summary | | Gemini
Genomics
PLC
is
a
clinical
genomics
company
that
uses
clinical
and
medical
information
as
a
starting
point
to
identify
relationships
between
genes,
human
health
and
disease.
The
Company
expects
that
its
discoveries
will
provide
it
with
licensable
products
that
pharmaceutical
and
diagnostic
companies
will
use
in
drug
discovery
and/or
gene-based
diagnostic
applications.
The
Company
already
has
comprehensive
and
diverse
clinical
and
genetic
resources
collected
by
its
clinical
collaborators
and
its
Canadian
subsidiary,
Newfound
Genomics,
from
human
volunteers,
databases
and
other
biological
information
management
and
analysis
(bioinformatic)
systems,
as
well
as
the
additional
resources
provided
by
its
technology
collaborators.
These
include
Celera
Genomics
(a
division
of
Applera
Corporation),
Qiagen
Genomics,
Large
Scale
Proteomics,
CuraGen,
Sequenom,
Rosetta
Inpharmatics
and
Genmab. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Gemini
Genomics
plc
is
a
clinical
genomics
company
that
identifies
relationships
between
human
genes
and
human
health
and
disease,
hoping
to
develop
products
that
can
be
licensed
to
pharmaceutical,
diagnostic,
genomics
and
biotechnology
companies.
For
the
three
months
ended
6/30/01,
the
Company
reported
no
revenue.
Net
loss
increased
44%
to
$7.2
million.
Higher
loss
reflects
increased
marketing
costs
and
$2.8
million
in
costs
related
to
the
proposed
merger
with
Sequenom. | More
from
Market Guide: Significant
Developments |
| | |
| Position | Michael Fitzgerald, 41 | Chairman | Paul Kelly, M.D., 40 | Pres,
CEO, Director | Tony Ratcliffe, 36 | CFO | M.C. Sullivan | Exec.
VP of Corp. Communications and Bioethics | Steven Butcher, Ph.D. | VP,
Scientific Operations |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|